Company Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors.
It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC.
The company is headquartered in San Diego, California.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 192 |
| CEO | Troy Wilson |
Contact Details
Address: 12730 High Bluff Drive, Suite 400 San Diego, California 92130 United States | |
| Phone | 858 500 8800 |
| Website | kuraoncology.com |
Stock Details
| Ticker Symbol | KURA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001422143 |
| CUSIP Number | 50127T109 |
| ISIN Number | US50127T1097 |
| Employer ID | 61-1547851 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Troy Edward Wilson J.D., Ph.D. | Chairman, Chief Executive Officer and President |
| Kathleen Ford | Chief Operating Officer |
| Teresa Brophy Bair Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Thomas Doyle | Senior Vice President of Finance and Accounting |
| Dr. Francis J. Burrows Ph.D. | Chief Scientific Officer |
| Dr. Roger Bakale Ph.D. | Senior Vice President of Manufacturing and Supply Chain |
| Maureen Clancy M.B.A. | Vice President and Global Head of Program Leadership and Project Management |
| Dr. Mollie Leoni M.D. | Chief Medical Officer |
| Brian T. Powl M.B.A., M.S. | Chief Commercial Officer |
| Samir Vattompadam M.S. | Senior Vice President of Global Program Leadership |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 19, 2025 | 144 | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 2, 2025 | SCHEDULE 13G/A | Filing |
| May 1, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 17, 2025 | ARS | Filing |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Apr 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2025 | DEF 14A | Other definitive proxy statements |